GAUSH MEDITECH (02407) has released its interim results for the 2026 fiscal year, reporting revenue of RMB 595 million, a year-on-year decrease of 8.9%. Net profit attributable to shareholders of the company stood at RMB 17.272 million, marking a significant drop of 54.52% compared to the previous period, with earnings per share of RMB 0.12.

According to the announcement, the decline in the group's distribution product revenue was driven by a combination of adverse factors, including shifts in market demand structure guided by national policies and the termination of agency cooperation for overseas femtosecond laser-assisted cataract surgery products. Despite these pressures, the group's self-owned product revenue achieved a growth of 4.6%, aligning with the company’s strategic development goals.

Looking ahead to the second half of 2026, the company anticipates that multiple self-developed products will enter mass production and launch, which is expected to drive sustained revenue growth and contribute to an overall improvement in the group's financial performance.